Healthcare / BiotechnologyNasdaqGM
$12.07
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-127.0M · quality 36.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
6/100
F
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$239M
P/E
N/A
•EV/EBITDA
N/A
•ROE
28.7%
↑Gross Margin
N/A
•Debt/Equity
N/A
•Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2019–2025 · 6 años de histórico normalizado
Revenue CAGR
+70.3%
FCF CAGR
—
FCF margin
43.4%
FCF / Net income
1.22x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $244.1M · net income $87.0M · FCF $106.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | $244.1M | $244.1M | $3.5M | $151000.00 | $0.00 | $20.1M | $0.00 | $10.0M |
| Net Income | $87.0M | $87.0M | $-187.4M | $-153.0M | $-104.7M | $-58.7M | $-45.4M | $-12.3M |
| EPS | 2.30 | 2.30 | -5.00 | -5.20 | -4.15 | -2.52 | -2.93 | — |
| Operating Margin | 27.7% | 27.7% | -5939.0% | -112543.7% | — | -280.5% | — | -105.6% |
| Net Margin | 35.7% | 35.7% | -5277.5% | -101319.2% | — | -292.3% | — | -123.4% |
| Cash Flow | ||||||||
| Free Cash Flow | $106.0M | $106.0M | $-162.8M | $-127.0M | $-71.3M | $-63.2M | $-37.2M | $-16.3M |
| Returns | ||||||||
| ROE | 28.7% | 28.7% | -32.8% | -46.1% | -37.7% | -24.2% | -17.3% | 63.4% |
| Growth & Yield | ||||||||
| Revenue Growth | 6775.0% | 6775.0% | 2251.0% | — | -100.0% | — | -100.0% | — |
| EPS Growth | 146.0% | 146.0% | 3.8% | -25.3% | -64.7% | 14.0% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
3Y implied EPS CAGR
-22.5%
EPS terminal req.
$1.07
Spread vs growth
168.5%
5Y implied EPS CAGR
-10.8%
EPS terminal req.
$1.30
Spread vs growth
156.8%
10Y implied EPS CAGR
-1.0%
EPS terminal req.
$2.09
Spread vs growth
147.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.